Everything below concerns alpha-MSH analogue. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-08-29. Numbers and descriptions here follow the published literature rather than marketing material.
Independent verification is central to quality control because the compound is not produced under pharmaceutical manufacturing standards. Third-party laboratories can measure purity, identity, residual solvents, and microbial contamination, though the scope of testing varies between services. Reported analyses of vendor samples have shown batch-to-batch variation in peptide content and the presence of truncated or oxidized species. How much of this variation reflects synthesis conditions versus storage and shipping is not well characterized. No harmonized reference standard exists for the material as sold.
Handling guidance for melanotan II follows general practice for small synthetic peptides rather than a product-specific monograph. Lyophilized powder is typically kept at minus twenty degrees Celsius or colder, protected from light and moisture, because warmth and humidity accelerate degradation. Once reconstituted, solutions are usually refrigerated and used within a short window, as hydrolysis and microbial growth both become concerns. Repeated freeze-thaw cycles are generally avoided. These conventions come from laboratory peptide chemistry and not from formal stability studies on this specific compound.
Analytical confirmation of identity relies on mass spectrometry, most often coupled to liquid chromatography. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and provides a purity estimate based on peak area. Electrospray ionization mass spectrometry then confirms the expected molecular mass, while tandem mass spectrometry can map the fragment sequence. For research-grade material, these two techniques together form the standard minimum. Purity figures reported by vendors are frequently not traceable to an independent laboratory.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form |
| Solubility | Freely soluble in water | Dissolves readily in aqueous buffer |
| Typical storage temperature | -20 °C or below | Protect from light and moisture |
| Typical analytical method | Reversed-phase HPLC and LC-MS | Purity estimate plus mass confirmation |
| Unit of measure | Milligram per vial | Content varies by vendor |
Freeze-dried melanotan-2 is normally kept as a desiccated powder at minus twenty degrees Celsius or lower, shielded from light and moisture. Peptides of this size degrade through hydrolysis, oxidation and deamidation, and each pathway accelerates as temperature and water activity rise. Repeated freeze-thaw cycles promote aggregation and loss of material, so aliquoting a stock solution before freezing is standard laboratory practice. Once dissolved, the solution is markedly less stable than the powder. In laboratory work, solutions are generally refrigerated and used within days rather than kept for months.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or oxidised impurities. Mass spectrometry, most often coupled to liquid chromatography, confirms molecular mass and detects substitutions that chromatography alone may miss. Amino acid analysis and peptide mapping supply additional structural evidence, while nuclear magnetic resonance is reserved for full structural confirmation. Laboratories that examine samples sold online report wide variation in actual content, with some vials containing little or none of the labelled material.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
=== Structure === The structure of a nanogel is dependent upon the synthesis mechanism and its application. Simple or traditional nanogels are nanoparticle-sized crosslinked polymer networks that swell in water. Hollow nanogels consisting only of an outer shell can increase the amount of cargo loaded into the platform. In other nanogel structures, the inner core and outer shell can be made of two different materials, such as a hydrophobic inner core to surround drugs or other small molecules and a hydrophilic outer shell that interacts with the external environment. The addition of a second linear monomer crosslinked to a nanogel is deemed a "hairy nanogel". Different nanogel synthesis methods can be completed in sequential order to create multilayered nanogels, such as starting with ionotropic gelation and then combining anionic and cationic polymers in an aqueous solution. Functionalized nanogels, in which targeting ligands or stimuli-sensitive functional groups are conjugated to the outer shell of a nanogel, are also important for certain nanogel applications.
== Habitat == Throughout their range, habitats preferred by American black bears have a few shared characteristics. They are often found in areas with relatively inaccessible terrain, thick understory vegetation and large quantities of edible material (especially masts). The adaptation to woodlands and thick vegetation in this species may have originally been because the bear evolved alongside larger, more aggressive bear species, such as the extinct giant short-faced bear and the grizzly bear, that monopolized more open habitats and the historic presence of larger predators, such as Smilodon and the American lion, that could have preyed on black bears. Although found in the largest numbers in wild, undisturbed areas and rural regions, American black bears can adapt to surviving in some numbers in peri-urban regions, as long as they contain easily accessible foods and some vegetative coverage. In most of the contiguous United States, American black bears today are usually found in heavily vegetated mountainous areas, from 400 to 3,000 m (1,300 to 9,800 ft) in elevation. For American black bears living in the American Southwest and Mexico, habitat usually consists of stands of chaparral and Pinyon–juniper woodlands. In this region, bears occasionally move to more open areas to feed on prickly pear cactus. At least two distinct, prime habitat types are inhabited in the Southeastern United States. American black bears in the southern Appalachian Mountains survive in predominantly oak-hickory and mixed mesophytic forests.
=== BBC Question Time appearance === On 5 February 2015, Galloway appeared on BBC's Question Time discussion programme, recorded in Finchley, London, within a constituency with Britain's largest Jewish community. The Jewish Chronicle wrote that "Galloway was heckled by Jewish audience members who challenged him on his anti-Israel record" and the audience shouted "You're not welcome here". Five days later, Hadley Freeman, a columnist for The Guardian, tweeted: "Galloway has said and done things that cross the line from anti-Israel to antisemitic". Galloway said that he would issue a suit for defamation against her. Freeman then deleted the tweet. Some who had re-tweeted Freeman's comment were then sent a letter from Chambers Solicitors, acting for Galloway, asking for an apology and £5,000 plus Value Added Tax (then levied at 20%) to cover costs incurred by the letter. Some people who received the letter complained to the Solicitors Regulation Authority. Eric Heinze, Professor of Law at Queen Mary University of London, noted that an editor of the Media Lens website had sent a tweet to Freeman asking if she could provide evidence for her claim that Galloway is antisemitic. Heinze wrote that "any example she could cite would probably persuade some and not others. Even if an overwhelming majority were unpersuaded, a highly popular opinion does not create an objectively verifiable fact." Chambers Solicitors' conduct was the subject of a warning from the SRA a year later. Initiating a libel action must begin within a year and no formal writ was issued.
== Weaknesses == The assay is limited to using existing restriction sites in the region of interest, and methylation that does not occur in the context of a specific restriction site will not be assayed. Incomplete digestion by restriction enzymes after PCR can confound the analysis: incomplete digestion would suggest lack of DNA methylation (if cutting with a methylation-sensitive enzyme such as HpaII). It is also known that BstUI can cut at unconverted sites, leading to overestimation of methylation levels and so the use of HpaII is often needed. In complex samples, cell-type heterogeneity can confound the analysis since the DNA is not being sequenced, heterogeneity in sequences from different cells in the sample (i.e. different cell populations within a tumor) that have acquired mutations in the interrogated region, such as changing the CG dinucleotide to CA or CT, would result in loss of the restriction site giving rise to an apparently methylated region due to lack of digestion. This would skew the quantification of DNA methylation levels in a given sample.
Sources: en.wikipedia.org
In the 1920s Otto Meyerhof was able to link together some of the many individual pieces of glycolysis discovered by Buchner, Harden, and Young. Meyerhof and his team were able to extract distinct glycolytic enzymes from muscle tissue, and combine them to artificially create the pathway from glycogen to lactic acid. In one paper, Meyerhof and scientist Renate Junowicz-Kockolaty investigated the reaction that splits fructose 1,6-diphosphate into the two triose phosphates. Previous work proposed that the split occurred via 1,3-diphosphoglyceraldehyde plus an oxidizing enzyme and cozymase. Meyerhoff and Junowicz found that the equilibrium constant for the isomerase and aldoses reaction were not affected by inorganic phosphates or any other cozymase or oxidizing enzymes. They further removed diphosphoglyceraldehyde as a possible intermediate in glycolysis. With all of these pieces available by the 1930s, Gustav Embden proposed a detailed, step-by-step outline of that pathway we now know as glycolysis. The biggest difficulties in determining the intricacies of the pathway were due to the very short lifetime and low steady-state concentrations of the intermediates of the fast glycolytic reactions. By the 1940s, Meyerhof, Embden and many other biochemists had finally completed the puzzle of glycolysis. The understanding of the isolated pathway has been expanded in the subsequent decades, to include further details of its regulation and integration with other metabolic pathways.
==== Voice acting ==== Ice-T's voice acting roles include Madd Dogg in the video game Grand Theft Auto: San Andreas, as well as Agent Cain in Sanity: Aiken's Artifact. He also appears as himself in Def Jam: Fight for NY and UFC: Tapout fighting video games. He also voiced the character Aaron Griffin in the video game Gears of War 3. Marrow also made an appearance in the 2019 video game Borderlands 3, in which he voices the character of BALEX. On August 22, 2023, it was revealed at Gamescom 2023 that he would be voicing the contractor, Mac in Payday 3.
Interaction with cell membrane receptors (extrinsic pathway) Interaction with mitochondria (intrinsic pathway) The first of these pathways involves the binding of a ligand to a receptor located on the surface of the cell membrane. The interaction of these two entities leads to the activation of various genes and releases a cascade of proteins characteristic of the apoptosis process. Arsenic trioxide also interacts with mitochondria. One of the initial changes in their structure induced by the drug is the opening of megachannels and the release of so-called "death proteins", primarily cytochrome c, APAF-1 (apoptotic peptidase activating factor 1), AIF (apoptosis-inducing factor), Smac/DIABLO protein, and endonucleases from the intermembrane space of mitochondria into the cytosol. In the cytoplasm, a protein complex known as the apoptosome forms, which activates further processes leading to apoptosis. Regardless of whether apoptosis is induced externally or internally, it always involves caspases, whose activation irreversibly leads the cell down the path of programmed cell death. Additionally, apoptosis is regulated by proteins from the Bcl-2 family, which can act as either pro-apoptotic or anti-apoptotic factors. The cause of acute promyelocytic leukemia is the translocation of the gene encoding the retinoic acid receptor (RARα) from chromosome 17 to a location near the PML gene on chromosome 15. This leads to the fusion of genes and the production of the PML/RARα protein. This protein inhibits differentiation and the death of the cells in which it is present.
Sources: en.wikipedia.org
The lyophilized powder is generally held at minus twenty degrees Celsius or below, away from light and moisture. Reconstituted solutions are typically refrigerated and used quickly. These practices derive from general peptide handling rather than a formal stability study.
Reversed-phase liquid chromatography estimates purity, and mass spectrometry confirms molecular mass. Together they distinguish the intended peptide from truncated or modified forms. Sequence-level confirmation may use tandem mass spectrometry or amino acid analysis.
Because it is not made under pharmaceutical standards, purity and content can vary between vendors and batches. Independent testing has documented labeling discrepancies. A certificate of analysis from an accredited laboratory offers more assurance than a vendor's own claim.
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.